In 49 patients with known Ebola virus disease outcomes during the ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus C (GBV-C). Fifty-three percent of these GBV-C ؉ patients survived; in contrast, only 22% of GBV-C ؊ patients survived. Both survival and GBV-C status were associated with age, with older patients having lower survival rates and intermediate-age patients (21 to 45 years) having the highest rate of GBV-C infection. Understanding the separate and combined effects of GBV-C and age on Ebola virus survival may lead to new treatment and prevention strategies, perhaps through age-related pathways of immune activation.
A
s of this writing, there have been 14,413 confirmed and probable infections and 5,177 deaths in the ongoing and worsening Ebola virus (EBOV) disease outbreak in West Africa (1) . Recently, EBOV sequences from Sierra Leone were obtained by unbiased deep sequencing. These patients represented approximately 70% of patients with Ebola virus disease in Sierra Leone from late May to mid-June of 2014 (2) .
In the three countries (Sierra Leone, Liberia, and Guinea) where the Ebola virus outbreak is concentrated, GB virus C (GBV-C, also known as human pegivirus) infects between 10 and 28% of individuals (3) (4) (5) (6) . Although GBV-C causes a prolonged high-titer viremia, GBV-C infection is largely considered to be benign (7, 8) . Intriguingly, several epidemiological studies have associated GBV-C infection with lower mortality in HIV-positive people (9-12; see reference 13 for a meta-analysis). Although potential mechanisms explaining this association are still under investigation, a growing body of evidence suggests that GBV-C prevents aberrant immune activation that is a hallmark of HIV pathogenesis and disease progression (i.e., AIDS) (see reference 14 for a review).
We reasoned that the relatively high prevalence of GBV-C in West Africa would result in a significant number of coinfections with EBOV. To examine GBV-C coinfections with EBOV, deepsequencing data initially published in reference 2 were downloaded from the NCBI Sequence Read Archive (SRA), sequencing run (SRR) files were converted into fastq files using the SRA toolkit, and SRR identifiers (IDs) were correlated with patient sample IDs using information from supplemental Table S2 in reference 2. Further analysis was confined to the 49 patients for whom EBOV infection outcome, age, and gender information were available (see Fig. S2 in the supplemental material in reference 2; also unpublished data). Samples for which two independent library preparations were performed or which were collected from the same individual at multiple time points were merged into single fastq files. fastq files were then imported into CLC Genomics Workbench 7 and short (Ͻ90-bp) and low-quality (Phred quality score ϽQ30) reads were removed. Samples labeled as potential dupli- cates in supplemental Table S2 of reference 2 were excluded from the analysis. Reads from all patients were aligned with moderate stringency (length fraction, 0.8; similarity fraction, 0.8; mismatch cost, 2; insertion and deletion cost, 3) against a full-genome GBV-C genotype 1 reference, the predominant genotype in West Africa (15) (GenBank accession number HGU36380). Up to 79,619 reads mapped to GBV-C per individual (Table 1) . A low level of carryover contamination is common in unbiased deep-sequencing experiments. We were therefore concerned that samples with low numbers of GBV-C reads might represent carryover from other samples with high levels of GBV-C. To more rigorously define samples as GBV-C positive or negative, we determined the GBV-C consensus sequence for each sample. We then remapped the reads from each sample against consensus sequences from all samples with high stringency (length fraction, 0.98; similarity fraction, 0.98; mismatch cost, 2; insertion and deletion cost, 3) and discarded reads that mapped to multiple consensus sequences. Twelve individuals had unambiguous evidence of GBV-C viremia supported by at least 100 uniquely mapped reads covering between 63 and 100% of the genome (Tables 1 and  2) . A 13th individual (G3764) was putatively categorized as GBV-C ϩ on the basis of 55 uniquely mapped reads, resulting in 38% coverage across the genome.
The 2014 EBOV sequences from Sierra Leone were on average 99.98% [99.98% to 100%] identical in pairwise comparisons across the genome (data not shown), which is consistent with the recency of this outbreak. In contrast, GBV-C sequences shared on average 91% (86.96 to 98.46%) nucleotide identity (Table 3) , suggesting preexisting GBV-C infections rather than cotransmission with EBOV.
Mortality in this cohort of 49 patients with sequence-confirmed EBOV infection was 69% overall, which is comparable to the 65% mortality reported for definitive infections in Sierra Leone before 18 August 2014 (1). Only 6/13 (46%) GBV-C ϩ individuals died, whereas 28/36 (78%) GBV-C Ϫ individuals died. Univariate analyses (Table 4) showed that older age was associated with higher mortality (OR, 1.06; P ϭ 0.0124) and that GBV-C ϩ status was associated with lower mortality (OR ϭ 0.25; P ϭ 0.0402). However, when these factors were considered together in a multivariate analysis (Table 4) , GBV-C status became nonsignificant (OR ϭ 0.25; P ϭ 0.0835), likely reflecting a confounding effect of age. Our finding of a relationship between older age and higher mortality is consistent with a recently published study (16) . However, GBV-C infection follows a different pattern, being most common in people aged 21 to 45 years ( Fig. 1) . Thus, age is associated with both EBOV survival and GBV-C status, but the pattern of association is different in each case. There were both epidemiological and technical aspects of this study that could not be controlled. For example, potentially confounding variables, such as comorbidities, rapidity of diagnosis, and relationships among patients, were not available. Furthermore, the samples were collected opportunistically, possibly introducing selection bias. It is also possible that we were not able to detect low-titer GBV-C viremia in some patients. Because sequencing reads were generated in an "unbiased" fashion, patients with very high EBOV titers may have "swamped" the sample, effectively reducing the number of GBV-C reads. We believe that this is unlikely because (i) we detected GBV-C in patients with EBOV plasma loads of Ͼ10 8 (see supplemental Fig. S2 in reference 2) and (ii) in previous studies, we have detected multiple viruses from a single sample using a similar methodology, even in samples where at least one virus was highly concentrated (17) (18) (19) (20) . Recovery of unique reads targeting the majority of the viral genome provide unequivocal evidence for GBV-C infection in all but one of the samples; however, in the one sample where less than half of the genome is covered, verification of GBV-C status using an independent assay (e.g., reverse transcription-quantitative PCR [RT-qPCR]) would be ideal but is not currently possible.
Nonetheless, these results demonstrate that approximately 27% of EBOV patients in this cohort are coinfected with GBV-C, an immunomodulatory virus that attenuates the pathogenesis of HIV. The association between GBV-C status and Ebola virus disease survival is intriguing, although confounded by age. We speculate that GBV-C may interact with the host immune system in ways that modulate the overexuberant immune response characteristic of EBOV-related pathogenesis (21) (22) (23) (24) (25) (26) (27) . However, our analyses are also consistent with a primary effect of age on both Ebola virus disease-related survival and GBV-C infection. Resolving the direction of causality would require additional data on the time course of infection and coinfection, as well as direct measures of immunity.
EBOV and GBV-C appear to infect different types of immune cells. EBOV infects primarily myeloid-lineage cells (28) (29) (30) (31) , while GBV-C appears to target lymphoid-lineage cells (32, 33) . The interaction of immune cell populations-both locally in lymphoid tissues and systemically via secreted factors-provides a biologically plausible mechanism for an interaction between GBV-C and EBOV. If GBV-C infection attenuates EBOV pathogenesis, it is possible that this occurs through modulation of the host immune response. In the context of HIV infection, GBV-C has been associated with a reduced production of proinflammatory cytokines and a reduction in T-cell activation in vivo and in vitro (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) . Conversely, robust production of proinflammatory cytokines and lymphocyte activation followed by massive T-cell death are thought to play a major role in EBOV pathogenesis and have been associated with poor clinical outcome in retrospective studies (21) (22) (23) (24) (25) (26) (27) .
Although our data are preliminary and potentially influenced by confounding variables, the results that we present here indicate a Pairwise comparisons of GBV-C consensus sequences were generated by aligning sequences with ClustalW. After manual adjustment, the percent nucleotide identity was calculated from the resulting 1,800-bp alignment.
that further study of GBV-C/EBOV coinfection may be warranted. Such investigations should endeavor to follow patients of different ages longitudinally and to collect immunological data, with the goal of establishing the temporal sequence of events that leads to EBOV-related survival and mortality, with and without coinfecting GBV-C. Nucleotide sequence accession number. We have made consensus GBV-C sequences available in GenBank (accession numbers KM670096 to KM670110).
ACKNOWLEDGMENTS
Five coauthors of the study that provided the original data used in the manuscript lost their lives to Ebola (45) . This paper would not have been possible without their courageous efforts. We thank all the authors of the original paper (2) for making their source data publicly available for reanalysis. We thank Erin Bailey, Thomas Friedrich, and Esper Kallas for helpful discussion. The funders of this research had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
